# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus

> **NCT01899703** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 22 (actual)

## Conditions studied

- Cholestasis, Intrahepatic

## Interventions

- **DRUG:** GSK2330672
- **DRUG:** Placebo
- **DRUG:** Ursodeoxycholic acid

## Key facts

- **NCT ID:** NCT01899703
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-10
- **Primary completion:** 2015-10-07
- **Final completion:** 2015-10-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01899703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01899703, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01899703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*